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Abstract
Background: The use of manipulation has long been advocated in the treatment of chronic
obstructive pulmonary disease (COPD), but few randomized controlled clinical trials have
measured the effect of manipulation on pulmonary function. In addition, the effects of individual
manipulative techniques on the pulmonary system are poorly understood. Therefore, the purpose
of this study was to determine the immediate effects of four osteopathic techniques on pulmonary
function measures in persons with COPD relative to a minimal-touch control protocol.
Methods: Persons with COPD aged 50 and over were recruited for the study. Subjects received
five, single-technique treatment sessions: minimal-touch control, thoracic lymphatic pump (TLP)
with activation, TLP without activation, rib raising, and myofascial release. There was a 4-week
washout period between sessions. Protocols were given in random order until all five techniques
had been administered. Pulmonary function measures were obtained at baseline and 30-minutes
posttreatment. For the actual pulmonary function measures and percent predicted values,
Wilcoxon signed rank tests were used to test within-technique changes from baseline. For the
percent change from baseline, Friedman tests were used to test for between-technique differences.
Results: Twenty-five subjects were enrolled in the study. All four tested osteopathic techniques
were associated with adverse posttreatment changes in pulmonary function measures; however,
different techniques changed different measures. TLP with activation increased posttreatment
residual volume compared to baseline, while TLP without activation did not. Side effects were mild,
mostly posttreatment chest wall soreness. Surprisingly, the majority of subjects believed they could
breathe better after receiving osteopathic manipulation.
Conclusion: In persons with COPD, TLP with activation, TLP without activation, rib raising, and
myofascial release mildly worsened pulmonary function measures immediately posttreatment
relative to baseline measurements. The activation component of the TLP technique appears to
increase posttreatment residual volume. Despite adverse changes in pulmonary function measures,
persons with COPD subjectively reported they benefited from osteopathic manipulation.
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Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality worldwide and is
becoming more prevalent [1]. The Global Initiative for
Chronic Obstructive Lung Disease (GOLD) defines COPD
"by airflow limitation that is not fully reversible. The air-
flow limitation is usually progressive and associated with
an abnormal inflammatory response of the lung to nox-
ious particles or gasses [1]." The GOLD statement adds
that "chronic airflow limitation characteristic of COPD is
caused by a mixture of small airway disease (obstructive
bronchiolitis) and parenchymal destruction (emphy-
sema), the relative contributions of which vary from per-
son to person [1]."
Using manipulation to treat COPD has a long tradition in
the osteopathic and chiropractic professions but remains
a novel approach in the larger biomedical community [2-
4]. Only a few studies have attempted to measure the
effects of manipulation using pulmonary function testing.
Ortley et al [5] found that osteopathic manipulation
caused no immediate change in pulmonary function
measures in normal healthy subjects. A crossover, control-
led clinical trial of asthma patients treated with chiroprac-
tic spinal manipulation twice weekly over 4 weeks found
no change in either forced expiratory volume in 1 second
(FEV1) or forced vital capacity (FVC) [6]. In postoperative
cholecystectomy patients, the thoracic lymphatic pump
technique was associated with a more rapid return to pre-
operative baseline in FEV1 and FVC on postoperative days
2 and 3, compared to an incentive spirometry control
group [7]. However, patients with mild COPD who
received twice weekly mobilization of musculoskeletal
restrictions plus the thoracic lymphatic pump for an
unspecified number of weeks showed no change in pul-
monary function measures [8]. A well designed study of
17 subjects with more advanced COPD treated over 9 to
12 months found osteopathic manipulative treatment
(OMT) significantly improved a non-validated severity of
illness score, which was calculated using arterial blood
gases and pulmonary function measures [9]. The use of
exercises to stretch respiratory muscles in persons with
COPD has been shown to improve chest wall mobility,
vital capacity, and dyspnea [10].
To determine the immediate effect of a multitechnique
osteopathic manipulative protocol in elderly persons with
COPD, Noll et al [11] conducted a controlled clinical trial
of 35 subjects who were randomized to receive either a
single, 20-minute light-touch protocol or a multitech-
nique OMT protocol. The multitechnique protocol com-
prised seven techniques: soft tissue to the paraspinal
thoracic muscles, rib raising, myofascial release to the
abdominal diaphragm, occipital decompression, myofas-
cial release to the thoracic inlet, pectoral traction, and the
thoracic lymphatic pump with activation. Somatic dys-
function not addressed by the standardized protocol was
treated with the operator's choice of myofascial release,
muscle energy, or high-velocity low-amplitude techniques
[11]. This study found a statistically significant 30-minute
posttreatment decrease in forced expiratory flow volume
at 25% (FEF25%) and forced expiratory flow volume at 25-
75% (FEF25-75%) in the OMT group. The OMT group also
showed a posttreatment increase in inspiratory capacity
(IC), residual volume (RV), total lung capacity (TLC), and
the RV/TLC ratio. These findings suggest an overall wors-
ening of air trapping in elderly persons with COPD imme-
diately following a multitechnique osteopathic
manipulative protocol [11].
The effects of individual manipulative techniques on the
pulmonary system remain poorly understood. The princi-
pal limitation of a multitechnique OMT protocol is that
the contribution of each individual technique to the final
result is unknown. While one technique may have a ben-
eficial effect, another may have a detrimental effect. There
remains a need to clarify the effects of individual tech-
niques. It is not certain that use of a single isolated manip-
ulative technique can change posttreatment pulmonary
function measures. Understanding the effects of individ-
ual techniques could lead to better protocols and modifi-
cations of individual techniques to improve efficacy. For
example, the multitechnique study discussed above [11]
used the thoracic lymphatic pump technique with activa-
tion, denoting the sudden removal of the hands from the
chest wall to trigger negative intrathoracic pressure result-
ing in a sudden rush of air into the lungs. It is possible that
activation may worsen residual volumes in persons with
COPD by enhancing air trapping and, thus, is relatively
contraindicated in this population.
Therefore, we conducted a randomized controlled trial to
investigate the immediate effects of individual osteo-
pathic manipulative techniques on pulmonary function
measures in persons with COPD. Four techniques were
evaluated: thoracic lymphatic pump (TLP) with activa-
tion, TLP without activation, rib raising, and myofascial
release. A minimal-touch treatment session was included
in the study as a control. Our primary hypothesis was that
the osteopathic techniques would cause measurable
changes in pulmonary function measures in persons with
COPD immediately following one treatment session. A
secondary hypothesis was that TLP with activation would
increase posttreatment residual volumes, while TLP with-
out activation would not. Subjects were asked about side
effects and their perceptions of the administered tech-
nique the day after each treatment session.Page 2 of 12
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Persons aged 50 years and over with a history of COPD
were recruited for the study. The inclusion criterion was
an FEV1/FVC ratio of 70% or less of the predicted value.
Potential subjects were identified by chart review or
screening office spirometry. Exclusion criteria were osteo-
pathic or chiropractic manipulation in the previous three
months, acute illness, active respiratory tract infection,
acute bone fracture, inability to cooperate, thoracic scolio-
sis greater than 25 degrees, or chest wall deformity. Study
treatments were given in an outpatient office setting in the
department of Internal Medicine at A.T. Still University's
Kirksville College of Osteopathic Medicine in Kirksville,
Missouri between June 2003 and January 2004. Individu-
als were recruited from the department's clinical practice,
newspaper advertisement, and speaking engagements on
local talk radio and with COPD support groups. Pulmo-
nary function testing was conducted in the pulmonary
function laboratory at Northeast Regional Medical Center.
Subjects were transported by wheelchair through connect-
ing indoor hallways between the office setting and the
pulmonary function laboratory to avoid fatigue. The study
was approved by the local institutional review board, and
all subjects gave informed consent.
Subjects received 5 single session treatment protocols in
random order until all 5 protocols had been given. The
duration of each treatment protocol was 5 minutes, except
the myofascial technique protocol which was 5 to 10 min-
utes in duration. Between each treatment session, there
was a 4-week washout period. The standardized treatment
protocols were administered as described below:
1) Minimal-touch control: The subject took five deep
breaths while the physician auscultated the lungs;
then the physician purposely auscultated the heart. No
attempt was made to represent the minimal-touch
protocol as an osteopathic manipulative technique.
Throughout the treatment session, the physician
engaged the subject in an empathetic discussion of
issues related to health and COPD.
2) Thoracic lymphatic pump with activation: The phy-
sician's hands were placed on the thoracic wall with
the thenar eminence of each hand over the pectoralis
muscles just below the clavicles; the fingers were
spread and angled toward the sides of the subject's
body to evenly distribute contact pressure across the
chest wall. The subject took a deep breath in and
exhaled. During exhalation, rhythmic, pumping
action was induced by alternating pressure on the
chest wall. At the end of exhalation, some residual
contact pressure was maintained on the chest wall,
and the subject was told to take another deep breath.
This procedure was repeated several times, each time
building a little more pressure on the thoracic wall.
On the fourth or fifth inhalation and during the first
one-third of the inhalation, the hands were very briskly
removed from the chest wall. This removal causes a
sudden release of the pressure built up in the chest
wall. The rib cage springs open, and a sudden increase
in thoracic negative pressure produces a rush or suck-
ing of air into the lungs.
3) Thoracic lymphatic pump without activation: The
physician's hands were placed on the thoracic wall
with the thenar eminence of each hand over the pecto-
ralis muscles just below the clavicles; the fingers were
spread and angled toward the sides of the subject's
body to evenly distribute pressure across the chest
wall. The subject took a deep breath in and exhaled.
During exhalation, rhythmic, pumping action was
induced by alternating pressure on the chest wall. At
the end of exhalation, some pressure was maintained
on the chest wall, and the subject was told to take
another deep breath. Thus, inhalation was taken
against some pressure on the chest wall. At the end of
three or four breathing cycles, the hands were slowly
withdrawn from the chest wall to avoid a sudden
change in chest wall pressures.
4) Rib raising: This technique was done with the sub-
ject in the supine position. The physician stood or sat
at the subject's side. The physician's hands were placed
under the subject's thorax, contacting the rib angles
with the pads of the fingers. The fingers were flexed,
and traction was applied to the rib angle. While trac-
tion was maintained, the physician used their arm as a
fulcrum and kept their wrists straight; rib angles were
raised anteriorly. After this cycle was repeated a
number of times and the ribs in that section had
improved mobility, the hands were moved up the tho-
racic cage, and another section was treated. This proce-
dure was repeated until all the ribs on one side of the
subject were treated. The procedure was then repeated
on the subject's alternate side.
5) Myofascial release: The physician treated any myo-
fascial structural asymmetry or restriction found in the
abdominal diaphragm, the thoracic rib cage, the tho-
racic inlet, or the cervical region with myofascial
release. Myofascial release was performed by the phy-
sician placing their hands on the subject's body, pal-
pating for the direction in which the tissues moved
most easily, moving the tissues in that direction, and
holding and feeling for a release or relaxation of the
tissues. The duration of the myofascial protocol ses-
sion was 5 to 10 minutes because the technique takes
longer to administer compared to the other tech-
niques.Page 3 of 12
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and 30-minutes posttreatment. Pulmonary function
measures included forced vital capacity (FVC) in liters,
forced expiratory volume in 1 second (FEV1) in liters, the
FEV1/FVC ratio in percent, the average forced expiratory
flow rate over the middle 50% of the FVC (FEF 25-75%) in
L/s, the maximum forced expiratory flow rate (FEFmax) in
L/s, expiratory time in seconds, and maximal voluntary
volume (MVV) in L/min. Lung volume measures were
slow vital capacity (SVC) in liters, inspiratory capacity
(IC) in liters, expiratory reserve volume (ERV) in liters,
total gas volume (TGV) in liters, residual volume (RV) in
liters, total lung capacity (TLC) in liters, and the RV/TLC
ratio as a percent. Airway resistance (Raw) in cm H2O/L/s
was also measured. Subjects were surveyed regarding pos-
sible side effects and of treatment perceptions by tele-
phone the day after each treatment session.
To ensure the quality of measurements, certified respira-
tory therapists conducted the pulmonary function tests
and used the American Thoracic Society criteria for test
reproducibility. Pulmonary function measures were
obtained with a MedGraphics® 1085 Series™, which meas-
ures lung volumes using plethysmography. The two oste-
opathic physicians who administered the treatments
reviewed and practiced the study techniques together
prior to enrolling subjects.
The osteopathic physicians and subjects were not blinded
to the order of the techniques assessed during the treat-
ment sessions. Subjects were told that their participation
as a volunteer would include five treatment sessions, each
with before and after measures of pulmonary function,
once every four weeks for approximately five months.
They were told the purpose of the project was to deter-
mine the effectiveness of four manipulative treatment
techniques for improving breathing and pulmonary func-
tion in persons with chronic obstructive pulmonary dis-
ease. Potential participants were told one of the sessions
would be a minimal-touch treatment. It was explained
that even minimal-touch may have beneficial effects,
which is why it was included in the study. While no spe-
cial effort was made to blind subjects to the treatment they
received (since this was not practical), no treatment ses-
sion was represented as being more beneficial than
another. Individuals involved with collecting the data,
conducting the pulmonary function testing, and perform-
ing the telephone survey were blinded to the specific tech-
nique performed during each testing session.
Sample size was determined using data from a previous
study [11]. The standard deviation of the total lung capac-
ity percent predicted value was estimated to be 25%.
Using a repeated measures analysis of variance (ANOVA),
a sample size of 25 has power of 0.80 (α = 0.05) to detect
a difference between two of the protocols of at least 9% or
0.36 standard deviations. The study statistician used
blocked randomization to assign subjects to one of five
treatment sequences, with randomization balanced after
five subjects. Additionally, treatments were randomly
assigned to one of two treatment providers. The treatment
sequence assignment slips were placed in sealed enve-
lopes and were opened by one of the treatment providers
after enrollment of a new subject.
Wilcoxon signed rank tests were used to test for baseline
to posttreatment changes on the actual pulmonary func-
tion measures and percent predicted values for each of the
five techniques. To compare the five techniques on their
immediate effects on pulmonary function measures,
Friedman tests were used on the percent change from
baseline to posttreatment with corresponding multiple
comparisons when appropriate. Subjects were included in
all comparisons for which they had complete data. P val-
ues less than .05 were considered statistically significant.
Cohen's d was used to estimate effect sizes.
Results
Participants
Twenty-five subjects were enrolled in the study (Figure 1).
Two subjects missed treatment sessions because of acute
illness; one missed one session due to a hospitalized
spouse and one missed two sessions due to an acute epi-
sode of pneumonia requiring hospitalization. One sub-
ject missed four of the five treatment sessions because of
poor compliance. None of the subjects experienced a
COPD exacerbation episode following any of the treat-
ments sessions. Subjects were aged 51 to 80 years with a
mean ± SD age of 68 ± 8 years. All subjects were Cauca-
sian. Demographic characteristics, including sex, smoking
habits, prior experience with manipulation, current med-
ical therapies for COPD, and common comorbid medical
conditions, are presented in Table 1.
Pulmonary function measures
The actual pulmonary function results at baseline and 30-
minutes posttreatment are summarized in Table 2. Meas-
ures with statistically significant changes from baseline to
posttreatment are highlighted. For the minimal-touch
control protocol, only IC (d = 0.57) showed a posttreat-
ment decrease from baseline. TLP with activation had
posttreatment decreases from baseline in FEFmax (d =
0.75), MVV (d = 0.59), SVC (d = 0.45), and ERV (d =
0.97); and posttreatment increases from baseline in RV (d
= 0.30) and the RV/TLC ratio (d = 0.31). For TLP without
activation, posttreatment FVC (d = 0.29), FEF25-75% (d =
0.38), and MVV (d = 0.52) decreased relative to baseline
and airway resistance (d = 0.30) increased relative to base-
line. Consistent with the study hypothesis, TLP with acti-
vation increased posttreatment RV compared to baselinePage 4 of 12
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Table 1: Demographic characteristics of subjects (N = 25)*
Variable Results Variable Results
Sex Atrovent updraft
Female 11 (44%) Yes 8 (35%)
Male 14 (56%) No 15 (65%)
Presently smoking Type II DM
Yes 9 (36%) Yes 4 (16%)
No 16 (64%) No 21 (84%)
Prior OMT History of stroke
Yes 21 (84%) Yes 2 (8%)
No 4 (16%) No 23 (92%)
Prior chiropractic treatment History of heart failure
Yes 22 (88%) Yes 2 (8%)
No 3 (12%) No 23 (92%)
Preference: OMT or chiropractic History of thyroid disease
OMT 11 (58%) Yes 3 (12%)
No preference 8 (42%) No 22 (88%)
Manipulation treatment for respiratory problem History of pulmonary tuberculosis
Yes 14 (56%) No 25 (100%)
No 11 (44%)
Frequency of manipulative treatment History of hypertension
More than 1 per year 4 (16%) Yes 7 (28%)
One or less per year 21 (84%) No 18 (72%)
Oxygen use History of coronary heart disease
Yes 12 (50%) Yes 7 (28%)
No 12 (50%) No 18 (72%)
Theophylline use History of pneumonia
Yes 2 (8%) Yes 20 (80%)
No 22 (92%) No 5 (20%)
Inhaled steroid use History of asthma
Yes 10 (42%) Yes 11 (44%)
No 14 (58%) No 14 (56%)
Oral steroid use History of cancer
Yes 6 (26%) Yes 10 (40%)
No 17 (74%) No 15 (60%)
Inhaled bronchodilator History of CABG
Yes 18 (75%) Yes 2 (8%)
No 6 (25%) No 22 (92%)
Updraft treatments History of lung surgery
Yes 13 (52%) Yes 2 (8%)
No 12 (48%) No 23 (92%)
Atrovent MDI Family history of lung disease
Yes 14 (58%) Yes 13 (54%)
No 10 (42%) No 11 (46%)
*Data are presented as number (% of subjects) for variables. Total counts may not add up to N due to missing values. All subjects were Caucasian.
OMT, osteopathic manipulative treatment; MDI, metered-dose inhaler; DM, diabetes mellitus; CABG, coronary artery bypass graft.
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Rib raising was associated with a posttreatment decrease
from baseline in FEFmax (d = 0.55) and MVV (d = 0.75).
Myofascial release was associated with a posttreatment
decrease from baseline in FEV1 (d = 0.53), FEF25-75% (d =
0.47), FEFmax (d = 0.60), MVV (d = 0.53), and SVC (d =
0.56).
The mean percent predicted values at baseline and 30-
minutes posttreatment are summarized in Table 3. Statis-
tically significant changes from baseline to posttreatment
are highlighted. The minimal-touch control was associ-
ated with significant decreases in both IC (d = 0.55) and
TLC (d = 0.42). TLP with activation decreased the percent
predicted values for FEFmax (d = 0.75), MVV (d = 0.58),
SVC (d = 0.48), and ERV (d = 0.97) and increased the per-
cent predicted value for RV (d = 0.31). TLP without activa-
tion decreased the FVC (d = 0.28), FEV1 (d = 0.34), FEF25-
75% (d = 0.39), FEFmax (d = 0.51), and MVV (d = 0.53), and
increased airway resistance (d = 0.29). Similar to the
actual pulmonary function results, TLP with activation
increased the percent predicted RV (d = 0.31), while TLP
without activation did not (d = 0.10). Rib raising
decreased the percent predicted values for FEFmax (d =
0.65) and MVV (d = 0.74). Myofascial release decreased
the percent predicted values for FEV1 (d = 0.52), FEF25-75%
(d = 0.49), FEFmax (d = 0.49), MVV (d = 0.56), and SVC (d
= 0.60).
The mean percent change values for each of the five tech-
niques are presented in Table 4. There were no significant
differences between the techniques on the percent change
from baseline to 30-minutes posttreatment.
Telephone survey results
Side effects reported during the posttreatment telephone
survey are summarized in Table 5. There were 14 separate
reports of side effects possibly associated with the study
treatments. None were characterized as severe. Muscu-
loskeletal soreness or pain was a common side effect. The
longest duration of these symptoms was reported to be
"two or three days." The minimal-touch control protocol
had the fewest reported side effects, with only one subject
reporting muscle soreness, which lasted "two or three
days" following the session. The subject attributed the
muscle soreness to the pulmonary function testing. TLP
with activation had the highest incidence of reported side
effects (19%), with TLP without activation a close second
(17%). For the rib raising technique, two of the three
reports indicated pain during the treatment. The myofas-
cial release technique had two reports of side effects, one
being posttreatment chest soreness and the other being rib
pain during treatment near the location of an old surgery.
Reported side effect rates were 6% for the minimal-touch
control technique and between 13% and 19% for the
osteopathic techniques.
Telephone survey responses relating to the subjects' per-
ception of the treatment sessions are summarized in Table
6. Survey responses from all study participants were not
obtained, primarily due to failure to contact some subjects
the day after a treatment session. In addition, a few sub-
jects declined to answer to some questions. The minimal-
touch control technique had the lowest percentage of pos-
itive responses. The majority of those subjects receiving
one of the four osteopathic techniques believed their
health benefited (53-76%) and they could breathe better
after treatment (50-79%). When asked if they would rec-
ommend the treatment to others, at least 90% of subjects
receiving one of the four osteopathic techniques said
"Yes." For the minimal-touch control technique, 71% of
subjects indicated they enjoyed receiving the treatment
and would recommend it to others.
Discussion
In the current study, all four osteopathic techniques
mildly worsened pulmonary function measures in per-
sons with COPD immediately following treatment. How-
ever, each technique had different effects on pulmonary
function. The TLP with activation technique was associ-
ated with a posttreatment increase in RV, while the same
technique without the activation component, that is TLP
without activation, was not associated with a posttreat-
ment rise in RV. This suggests that it is the activation com-
ponent of the technique that causes a posttreatment
increase in RV. Despite this adverse change, 74% of sub-
jects who received TLP with activation reported the treat-
ment helped them breathe better. Only 57% of subjects
who received TLP without activation believed the treat-
ment helped them breathe better even though RV was not
adversely affected by this technique. As expected, the min-
imal-touch control was associated with the fewest pulmo-
nary function changes with only the posttreatment IC and
TLC being decreased. Within-technique analysis showed
that all four osteopathic techniques reduced MVV for both
actual and percent predicted values. The TLP with activa-
tion technique caused the largest number of adverse pul-
monary function changes. Rib raising had the fewest
adverse changes.
To our knowledge, this is the first study to test the imme-
diate effects of individual osteopathic techniques on pul-
monary function measures in persons with COPD.
However, one of the techniques used in the current study,
the TLP, has been studied more extensively than the oth-
ers. The TLP technique was first described by Miller in
1927 [12]. It was specifically developed to treat pneumo-
nia and was intended to enhance bacterial antigen absorp-Page 6 of 12
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lymphatic circulation and, thus, stimulate a quicker anti-
body response [12]. Recent animal model studies have
confirmed that lymphatic pumping does increase lym-
phatic flow through the thoracic duct [13]. Animal model
studies have also shown that the concentration of leuko-
cytes in thoracic duct lymph are significantly increased by
lymphatic pumping [14]. In 1935, Morey was the first to
describe activation with the TLP technique: he developed
the activation component of the technique to enhance
lymphatic flow [15]. The TLP with activation technique
has been utilized in the protocols of several studies that
examine the use of OMT in the elderly hospitalized with
pneumonia [16-18]. This technique is thought to be help-
ful in countering pulmonary atelectasis. A study evaluat-
ing the use of TLP for atelectasis in postoperative
cholecystectomy patients found a more rapid postopera-
tive improvement in FEV1 and FVC in a TLP-treated group
relative to a conventional incentive spirometry group [7].
However, since the technique description indicates that
the resistive force on the chest wall was "gently released"
toward the end of the fifth inspiration [7], the TLP tech-
nique used in this study probably did not incorporate acti-
vation. Future studies are needed to determine if the
activation component of the TLP technique increases lym-
phatic circulation and to determine the efficacy of this
technique in treating or preventing atelectasis.
Reported side effects were relatively mild and transitory.
The majority were related to musculoskeletal soreness or
pain either during a treatment session or following a treat-
ment session. Vick et al [19] reviewed the safety of manip-
ulative treatment from 1925 to 1993 and found 185
reports of serious adverse events but no published reports
of minor or transitory complications. Mild to moderate
side effects associated with manipulation are likely under-
reported and poorly characterized. In a small study of
OMT in nursing home residents [20], 1 out of 7 partici-
pants (14%) who answered a posttreatment question-
naire reported musculoskeletal soreness. In a previous
study that tested the immediate effects of a multitech-
nique osteopathic protocol in persons with COPD [11], 2
out of 15 surveyed participants (12%) reported posttreat-
ment muscle soreness. These published side effect rates
are consistent with the 13-17% reported side effect rates
for each of the four osteopathic techniques of the current
study.
Despite the posttreatment worsening of pulmonary func-
tion measures, the majority of subjects reported that their
health benefited from treatment, that they could breathe
better after each treatment, that treatments were enjoya-
ble, and that they would recommend the treatment to
others. Favorable survey responses for the minimal-touch
control session were fewer, but subjects seemed to value
the auscultation and the empathetic discussion of their
health issues. A previous osteopathic multitechnique
study also found that the majority of participants believed
that they benefited from manipulative treatment, despite
objective worsening of pulmonary function measures
[11]. In that study [11], 71% of subjects reported their
health benefited from treatment, 82% reported they could
breath better after treatment, 94% said they enjoyed the
treatment, and 88% reported they would recommend the
treatment to others. These published results are similar to
the results of the current study.
There are several mechanistic explanations for the study
findings. Persons with COPD have chronic airway inflam-
mation and are prone to bronchospasm and air trapping.
The physical movement associated with the osteopathic
techniques may trigger bronchospasm or loosen airway
secretions, which could worsen air trapping. This problem
may be limited to those with diseased airways since nor-
mal airways are likely to respond differently. The subjec-
tive sense of improvement following treatment despite
worsening pulmonary function measures seems paradox-
ical. Belief in the treatment and the placebo effect are pos-
sible explanations. There is evidence that manipulation
promotes a sense of well-being and decreases pain by
modulating endocannabinoids, endogenous opioids, and




Missed protocol treatment sessions 
 Acute illness (n=3)  
 Missed appointment (n=4) 
Five single-technique treatment sessions with  
baseline and posttreatment pulmonary function 
testing 
 Minimal-touch control (n=24) 
 TLP with activation (n=24) 
 TLP without activation (n=24) 
 Rib raising (n=23) 
 Myofascial release (n=22) 
37 subjects assessed 
for eligibility 
Excluded: Did not meet study 
criteria (n=12) 
Entered stratified 
randomization (n=25) Page 7 of 12
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to the posttreatment survey.
The current study has several limitations. Pulmonary
function testing was only done at baseline and approxi-
mately 30-minutes posttreatment. The duration of any
treatment effects on pulmonary function measures
beyond 30 minutes is unknown. It is possible that the
techniques had a beneficial effect on pulmonary function
measures after the initial posttreatment decline. More
likely, however, the pulmonary function measures
returned to baseline. We did not use functional measures,
Table 2: Baseline and posttreatment actual pulmonary function results for each technique
Technique Minimal-touch Control TLP with Activation TLP Without Activation Rib Raising Myofascial Release
FVC (L) 2.79 ± 0.99 2.83 ± 1.05 2.91 ± 1.05 2.75 ± 1.02 2.83 ± 1.02
2.80 ± 0.97 2.79 ± 1.00 2.85 ± 1.01 2.77 ± 1.05 2.79 ± 0.97
P = 0.65 P = 0.31 P = 0.02 P = 0.85 P = 0.12
FEV1 (L) 1.57 ± 0.79 1.59 ± 0.82 1.63 ± 0.78 1.51 ± 0.79 1.56 ± 0.75
1.57 ± 0.79 1.58 ± 0.81 1.59 ± 0.75 1.53 ± 0.82 1.52 ± 0.71
P = 0.90 P = 0.40 P = 0.07 P = 0.45 P = 0.03
FEV1/FVC (%) 55 ± 13 54 ± 13 55 ± 13 53 ± 12 54 ± 12
54 ± 13 55 ± 14 55 ± 13 54 ± 13 53 ± 11
P = 0.67 P = 0.73 P = 0.63 P = 0.46 P = 0.46
FEF25-75% (L/s) 0.81 ± 0.62 0.80 ± 0.61 0.82 ± 0.55 0.73 ± 0.52 0.75 ± 0.52
0.78 ± 0.62 0.81 ± 0.59 0.75 ± 0.51 0.77 ± 0.62 0.68 ± 0.46
P = 0.26 P = 0.30 P = 0.006 P = 0.56 P = 0.007
FEFmax (L/s) 4.55 ± 2.28 4.75 ± 2.34 4.79 ± 2.35 4.68 ± 2.35 4.69 ± 2.31
4.41 ± 2.32 4.43 ± 2.16 4.55 ± 2.27 4.37 ± 2.31 4.42 ± 2.37
P = 0.38 P = 0.001 P = 0.08 P = 0.01 P = 0.007
Expiratory time (s) 9.60 ± 1.63 9.54 ± 1.62 9.79 ± 2.52 10.00 ± 1.90 9.78 ± 1.74
9.74 ± 1.77 9.99 ± 2.60 9.29 ± 1.95 10.37 ± 2.08 10.06 ± 2.01
P = 0.53 P = 0.65 P = 0.055 P = 0.27 P = 0.42
MVV (L/min) 56 ± 30 58 ± 29 60 ± 31 56 ± 31 58 ± 30
56 ± 30 55 ± 29 57 ± 30 52 ± 28 55 ± 30
P = 0.64 P = 0.005 P = 0.02 P = 0.0004 P = 0.03
SVC (L) 2.91 ± 1.05 2.98 ± 1.08 3.05 ± 1.10 2.82 ± 1.05 3.07 ± 1.09
2.90 ± 1.14 2.87 ± 1.04 2.98 ± 1.10 2.85 ± 1.12 2.95 ± 1.06
P = 0.42 P = 0.04 P = 0.09 P = 0.81 P = 0.008
IC (L) 2.14 ± 0.78 2.10 ± 0.80 2.13 ± 0.79 2.00 ± 0.73 2.14 ± 0.77
2.03 ± 0.72 2.12 ± 0.76 2.09 ± 0.76 2.06 ± 0.78 2.10 ± 0.76
P = 0.008 P = 0.42 P = 0.38 P = 0.84 P = 0.19
ERV (L) 0.77 ± 0.44 0.88 ± 0.45 0.92 ± 0.51 0.82 ± 0.52 0.93 ± 0.55
0.87 ± 0.62 0.75 ± 0.44 0.89 ± 0.64 0.79 ± 0.52 0.86 ± 0.48
P = 0.18 P<0.0001 P = 0.22 P = 0.42 P = 0.30
TGV (L) 4.14 ± 0.91 4.17 ± 0.88 4.29 ± 0.97 4.32 ± 1.13 4.35 ± 1.05
4.07 ± 0.90 4.18 ± 0.91 4.23 ± 1.03 4.16 ± 1.05 4.33 ± 1.08
P = 0.43 P = 0.56 P = 0.16 P = 0.19 P = 0.91
RV (L) 3.36 ± 0.81 3.30 ± 0.77 3.38 ± 0.92 3.50 ± 1.21 3.41 ± 0.96
3.19 ± 0.84 3.41 ± 0.93 3.33 ± 0.99 3.37 ± 1.01 3.48 ± 1.08
P = 0.15 P = 0.03 P = 0.48 P = 0.62 P = 0.34
TLC (L) 6.27 ± 1.16 6.27 ± 1.14 6.41 ± 1.11 6.32 ± 1.31 6.47 ± 1.23
6.10 ± 1.03 6.29 ± 0.99 6.33 ± 1.21 6.21 ± 1.14 6.44 ± 1.27
P = 0.07 P = 0.41 P = 0.22 P = 0.39 P = 0.34
RV/TLC (%) 54 ± 12 53 ± 12 53 ± 13 55 ± 13 53 ± 13
53 ± 13 55 ± 14 53 ± 13 55 ± 14 54 ± 13
P = 0.59 P = 0.04 P = 0.79 P = 0.85 P = 0.058
Raw (cm H2O/L/s) 4.09 ± 3.18 3.94 ± 3.15 3.36 ± 2.19 4.30 ± 3.09 4.44 ± 3.17
4.05 ± 2.76 3.94 ± 2.74 4.04 ± 3.20 4.22 ± 3.11 4.06 ± 2.75
P = 0.95 P = 0.82 P = 0.04 P = 0.30 P = 0.75
Results are reported as mean ± SD. Wilcoxon signed rank tests were used to test for significant baseline to posttreatment within-technique 
changes. Measures with significant within-technique changes are highlighted.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25-75%, average forced expiratory flow rate over the middle 50% of the 
FVC; FEFmax, maximum forced expiratory flow rate; MVV, maximal voluntary volume; SVC, slow vital capacity; IC, inspiratory capacity; ERV, 
expiratory reserve volume; TGV, total gas volume; RV, residual volume; TLC, total lung capacity; Raw, airway resistance.Page 8 of 12
(page number not for citation purposes)
Osteopathic Medicine and Primary Care 2009, 3:9 http://www.om-pc.com/content/3/1/9such as a 6-minute walk or serologic markers, in the cur-
rent study. While the sample size was large enough to
detect moderate differences between the techniques, the
results should be interpreted with caution because of the
relatively small sample size and because these results have
not been confirmed by other studies. Blinding was limited
to those collecting the data. Because no attempt was made
to blind the subjects, they were not asked which session
they thought was the minimal-touch control. Conclu-
sions based on the posttreatment survey results are also
limited because the survey was not a validated instrument
and the responses were subjective.
The findings of this study have good external validity to
persons with clinically stable COPD since the study
cohort included persons with common comorbid medical
conditions. However, our results have less generalizability
with other conditions, such as asthma or normal lung
function. Therefore, results of the current study are appli-
cable to the techniques tested and cannot be generalized
to other osteopathic techniques.
Despite the adverse changes in pulmonary function meas-
ures, the four osteopathic techniques appear to be reason-
ably safe for persons with stable COPD. The four
techniques were shown to be "safe" in the sense that none
of the study participants reported an acute exacerbation of
symptoms which required a change in medical treatment
or resulted in hospitalization. Also, the majority of sub-
jects reported feeling and breathing better after treatment.
Table 3: Baseline and posttreatment percent predicted values for each technique
Technique Minimal-touch Control TLP with Activation TLP Without Activation Rib Raising Myofascial Release
FVC 82 ± 22 83 ± 23 84 ± 24 81 ± 22 82 ± 24
82 ± 21 82 ± 21 83 ± 23 82 ± 22 81 ± 23
P = 0.58 P = 0.37 P = 0.03 P = 0.65 P = 0.26
FEV1 58 ± 25 58 ± 24 59 ± 25 56 ± 23 57 ± 25
58 ± 24 58 ± 24 58 ± 24 57 ± 25 56 ± 24
P = 0.83 P = 0.37 P = 0.04 P = 0.39 P = 0.04
FEF25-75% 29 ± 18 28 ± 17 29 ± 18 26 ± 16 27 ± 17
28 ± 18 29 ± 18 27 ± 17 27 ± 19 24 ± 16
P = 0.31 P = 0.30 P = 0.006 P = 0.57 P = 0.009
FEFmax 70 ± 29 73 ± 28 72 ± 30 73 ± 30 71 ± 30
68 ± 28 68 ± 27 68 ± 29 68 ± 29 67 ± 31
P = 0.29 P = 0.002 P = 0.04 P = 0.006 P = 0.009
MVV 52 ± 23 53 ± 21 55 ± 24 52 ± 23 53 ± 24
52 ± 24 51 ± 21 52 ± 24 49 ± 21 51 ± 23
P = 0.75 P = 0.006 P = 0.02 P = 0.0006 P = 0.02
SVC 79 ± 20 81 ± 20 81 ± 23 77 ± 19 81 ± 22
78 ± 22 78 ± 20 79 ± 22 78 ± 21 78 ± 21
P = 0.41 P = 0.04 P = 0.07 P = 0.65 P = 0.01
IC 79 ± 23 76 ± 21 77 ± 24 74 ± 19 77 ± 23
75 ± 21 78 ± 21 75 ± 21 76 ± 21 76 ± 21
P = 0.01 P = 0.34 P = 0.34 P = 0.76 P = 0.22
ERV 80 ± 35 94 ± 37 97 ± 48 87 ± 40 93 ± 45
88 ± 47 78 ± 34 92 ± 55 82 ± 40 87 ± 39
P = 0.22 P < 0.0001 P = 0.22 P = 0.42 P = 0.22
TGV 130 ± 30 131 ± 31 134 ± 34 136 ± 34 134 ± 33
127 ± 29 131 ± 31 132 ± 34 131 ± 34 134 ± 33
P = 0.47 P = 0.62 P = 0.18 P = 0.21 P = 0.99
RV 150 ± 41 147 ± 38 151 ± 45 156 ± 54 152 ± 46
143 ± 42 152 ± 44 149 ± 48 151 ± 48 155 ± 48
P = 0.17 P = 0.04 P = 0.51 P = 0.59 P = 0.35
TLC 107 ± 16 106 ± 15 108 ± 17 108 ± 17 108 ± 16
104 ± 15 107 ± 15 106 ± 18 106 ± 16 108 ± 17
P = 0.048 P = 0.44 P = 0.16 P = 0.45 P = 0.36
Raw 246 ± 175 234 ± 170 205 ± 124 249 ± 192 275 ± 199
243 ± 151 237 ± 157 248 ± 202 250 ± 167 247 ± 153
P = 0.89 P = 0.81 P = 0.046 P = 0.28 P = 0.83
Results are reported as mean ± SD. Wilcoxon signed rank tests were used to analyze for significant baseline to posttreatment within-technique 
changes. Measures with significant within-technique changes are highlighted.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25-75%, average forced expiratory flow rate over the middle 50% of the 
FVC; FEFmax, maximum forced expiratory flow rate; MVV, maximal voluntary volume; SVC, slow vital capacity; IC, inspiratory capacity; ERV, 
expiratory reserve volume; TGV, total gas volume; RV, residual volume; TLC, total lung capacity; Raw, airway resistance.Page 9 of 12
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Table 4: Baseline to posttreatment percent changes
Technique Minimal-touch 
Control
TLP with Activation TLP Without 
Activation
Rib Raising Myofascial Release P Value
FVC 0.7 ± 5.0 0.3 ± 11.9 -1.4 ± 8.1 0.7 ± 8.3 -0.7 ± 6.2 0.67
FEV1 0.6 ± 6.6 0.2 ± 7.8 -1.0 ± 7.8 1.2 ± 8.0 -1.4 ± 6.8 0.10
FEV1/FVC -0.2 ± 5.3 0.3 ± 9.8 0.4 ± 4.0 0.7 ± 6.4 -0.4 ± 5.3 0.71
FEF25-75% -2.4 ± 13.8 3.3 ± 23.4 -5.5 ± 21.9 0.7 ± 22.5 -7.3 ± 17.8 0.12
FEFmax -2.4 ± 14.5 -6.3 ± 9.3 -5.6 ± 12.6 -6.1 ± 13.7 -5.5 ± 17.3 0.25
Expiratory time 1.9 ± 11.4 5.0 ± 20.9 -3.6 ± 12.4 5.2 ± 19.0 3.5 ± 15.5 0.48
MVV -0.0 ± 10.5 -4.9 ± 10.7 -4.6 ± 8.6 -5.7 ± 10.1 -5.7 ± 9.6 0.40
SVC -0.3 ± 7.7 -3.2 ± 7.2 -2.0 ± 7.4 0.6 ± 15.5 -3.5 ± 6.3 0.51
IC -3.7 ± 9.9 2.5 ± 9.2 -0.6 ± 10.6 2.7 ± 14.3 -1.2 ± 10.1 0.21
ERV 10.9 ± 38.3 -12.4 ± 31.3 -6.9 ± 19.4 3.7 ± 59.8 -1.1 ± 30.9 0.09
TGV -1.3 ± 8.2 0.6 ± 8.6 -1.6 ± 8.0 -3.2 ± 9.1 -0.2 ± 7.2 0.19
RV -4.1 ± 17.4 3.2 ± 14.2 -1.3 ± 12.4 -1.9 ± 13.9 2.3 ± 11.1 0.10
TLC -2.2 ± 6.1 1.1 ± 7.2 -1.4 ± 5.9 -1.1 ± 5.7 -0.5 ± 5.3 0.36
RV/TLC -2.4 ± 14.5 1.6 ± 10.1 -0.2 ± 7.6 -1.2 ± 10.4 2.8 ± 7.4 0.21
Raw 3.0 ± 27.5 5.9 ± 33.3 22.9 ± 46.1 1.2 ± 28.8 0.7 ± 30.9 0.53
Results are reported as mean ± SD. Friedman tests were used to test for differences between the techniques.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25-75%, average forced expiratory flow rate over the middle 50% of the 
FVC; FEFmax, maximum forced expiratory flow rate; MVV, maximal voluntary volume; SVC, slow vital capacity; IC, inspiratory capacity; ERV, 
expiratory reserve volume; TGV, total gas volume; RV, residual volume; TLC, total lung capacity; Raw, airway resistance.
Table 5: Reported study side effects surveyed by telephone the day after each treatment session*






Rib Raising Myofascial Release
Subject A B C B D
Reported Side Effect PFT made sore for 2 
or 3 days
Chest pain in middle 
for 24 hours
Soreness in front 
chest
Chest pain during the 
procedure
Soreness in chest for 
1 day
Subject E F F G
Reported Side Effect Soreness in the chest, 
remains next day
Stiff neck and 
headache the next day
Tired back During the treatment, 
not afterwards, sore 
in lower ribs near 
(old) surgery site
Subject H I J
Reported Side Effect Chest pressure during 
treatment, pain for 2-
3 days
Sore in chest later 
that night lasted until 
next day, and chest 
congestion




Reported Side Effect Cramps in left lung Discomfort across the 
back afterwards
Reported Side Effect 
Rate
1 out of 18
(6%)
4 out of 23
(17%)
4 out of 21
(19%)
3 out of 20
(15%)
2 out of 16
(13%)
TLP, thoracic lymphatic pump; PFT, pulmonary function testing.
* Paraphrased from subjects' reports.
Osteopathic Medicine and Primary Care 2009, 3:9 http://www.om-pc.com/content/3/1/9Because of the small sample size, conclusions regarding
safety should be made with caution. Symptomatic exacer-
bations are common in this population. If the number of
participants had been larger, it is likely such cases would
have occurred regardless of group assignment. However,
in the context of an acute exacerbation of COPD, where
even small transient adverse changes may have serious
consequences, these techniques should be considered
contraindicated. Further, the TLP with activation and
myofascial release techniques may be relatively contrain-
dicated even in persons with stable COPD since these
techniques may increase RV. It is important to collect
information on side effects and adverse events even in
small clinical trials such as this one, so that a body of lit-
erature can be developed on the tolerability of various
manipulative techniques.
Conclusion
The four osteopathic techniques of the current study --
TLP with activation, TLP without activation, rib raising,
and myofascial release -- were associated with a modest
posttreatment worsening of pulmonary function meas-
ures in persons with COPD. The different techniques had
different effects on the pulmonary function measures. The
activation component of the TLP technique increased RV
in persons with COPD. Side effects were relatively mild
and transitory, and were related to posttreatment chest
wall soreness. Overall, the techniques tested worsened
pulmonary function at thirty minutes posttreatment in
persons with COPD. Paradoxically, the majority of sub-
jects believed they could breathe better after receiving the
osteopathic treatments. The longer term effects of these
techniques on pulmonary function are still not known.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DRN conceived the study, participated in its design,
acquired and interpreted the data, and drafted the manu-
script. JCJ participated in the study design, performed the
statistical analyses, and revised the manuscript for con-
tent. RWB participated in the study design, acquired and
interpreted the data, and revised the manuscript for con-
tent. EJS acquired the data and revised the manuscript for
content. All authors read and approved the final manu-
script.
Acknowledgements
This study was funded by a grant from the American Osteopathic Associa-
tion/Osteopathic Heritage Foundation, grant no. OHF-02-07-527. The 
funding body had no role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the manuscript; or in the decision 
to submit the manuscript for publication. The authors would like to thank 
the following: William Sexton, PhD, Philip Slocum, DO, and Herbert Yates, 
DO, for their contributions to the study design; Selina Burt, DO, for her 
role as research coordinator of the study; the staff of the Northeast 
Regional Medical Center's pulmonary function laboratory; and Deborah 
Goggin, MA, for her editorial assistance.
References
1. Global Initiative for Chronic Obstructive Lung Disease: Global
Strategy for the Diagnosis, Management, and Prevention of
Table 6: Subject perceptions of the treatment sessions surveyed by telephone the day after each session
Question Minimal-touch 
Control
TLP with Activation TLP Without 
Activation
Rib Raising Myofascial Release
Do you believe your health 
has benefited from the most 
recent manipulation 












Do you feel that you 
breathed better after the 
most recent manipulation 












Did you enjoy receiving the 
most recent manipulation 











Would you recommend the 












Subjects were asked to respond "Yes" or "No" to the questions in the table. Results are presented as the percentage of "Yes" responses and the 
total number of responses for each question.
TLP, thoracic lymphatic pump.Page 11 of 12
(page number not for citation purposes)
Osteopathic Medicine and Primary Care 2009, 3:9 http://www.om-pc.com/content/3/1/9Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Chronic Obstructive Pulmonary Disease.   [http://www.gold
copd.org/Guidelineitem.asp?l1=2&l2=1&intId=996].
2. Kuchera ML, Kuchera WA: Osteopathic Considerations in Systemic Dys-
function Kirksville, MO: KCOM Press; 1990. 
3. Masarsky CS, Weber M: Chiropractic management of chronic
obstructive pulmonary disease.  J Manipulative Physiol Ther 1988,
11:505-510.
4. Stiles EG: Manipulative management of chronic lung disease.
Osteopath Ann 1981, 9:300-304.
5. Ortley GR, Sarnwick RD, Dahle RE, Roode TD, Zink JG, Kilmore MA:
Recording of physiologic changes associated with manipula-
tion in healthy subjects [abstract].  J Am Osteopath Assoc 1980,
80:228-229.
6. Nielsen NH, Bronfort G, Bendix T, Madsen F, Weeke B: Chronic
asthma and chiropractic spinal manipulation: a randomized
clinical trial.  Clin Exp Allergy 1995, 25:80-88.
7. Sleszynski SL, Kelso AF: Comparison of thoracic manipulation
with incentive spirometry in preventing postoperative atel-
ectasis.  J Am Osteopath Assoc 1993, 93:834-838. 843-845
8. Miller WD: Treatment of visceral disorders by manipulative
therapy.  In The Research Status of Spinal Manipulative Therapy Edited
by: Goldstein M. US Department of Health, Education and Welfare;
1975:295-301.  [NINCDS Monograph No. 15.]
9. Howell RK, Allen TW, Kappler RE: The influence of osteopathic
manipulative therapy in the management of patients with
chronic obstructive lung disease.  J Am Osteopath Assoc 1975,
74:757-760.
10. Kakizaki F, Shibuya M, Yamazaki T, Yamada M, Suzuki H, Homma I:
Preliminary report on the effects of respiratory muscle
stretch gymnastics on chest wall mobility in patients with
chronic obstructive pulmonary disease.  Respir Care 1999,
44:409-414.
11. Noll DR, Degenhardt BF, Johnson JC, Burt SA: Immediate effects
of osteopathic manipulative treatment in elderly patients
with chronic obstructive pulmonary disease.  J Am Osteopath
Assoc 2008, 108:251-259.
12. Miller CE: The specific cure of pneumonia.  J Am Osteopath Assoc
1927, 27:35-38.
13. Knott EM, Tune JD, Stoll ST, Downey HF: Increased lymphatic
flow in the thoracic duct during manipulative intervention.  J
Am Osteopath Assoc 2005, 105:447-456.
14. Hodge LM, King HH, Williams AG Jr, Reder SJ, Belavadi T, Simecka
JW, et al.: Abdominal lymphatic pump treatment increases
leukocyte count and flux in thoracic duct lymph.  Lymphat Res
Biol 2007, 5:127-133.
15. Morey LW: The lymphatic pump in diabetes mellitus: good
results secured through carefully timed treatment.  Osteopath
Prof 1935, 2:25-27. 48-52
16. Noll DR, Degenhardt BF, Fossum C, Hensel K: Clinical and
research protocol for osteopathic manipulative treatment of
elderly patients with pneumonia.  J Am Osteopath Assoc 2008,
108:508-516.
17. Noll DR, Shores J, Bryman PN, Masterson EV: Adjunctive osteo-
pathic manipulative treatment in the elderly hospitalized
with pneumonia: a pilot study.  J Am Osteopath Assoc 1999,
99:143-146. 151-152
18. Noll DR, Shores JH, Gamber RG, Herron KM, Swift J Jr: Benefits of
osteopathic manipulative treatment for hospitalized elderly
patients with pneumonia.  J Am Osteopath Assoc 2000,
100:776-782.
19. Vick DA, McKay C, Zengerle CR: The safety of manipulative
treatment: review of the literature from 1925 to 1993.  J Am
Osteopath Assoc 1996, 96:113-115.
20. Noll DR, Degenhardt BF, Stuart M, McGovern R, Matteson M: Effec-
tiveness of a sham protocol and adverse effects in a clinical
trial of osteopathic manipulative treatment in nursing home
patients.  J Am Osteopath Assoc 2004, 104:107-113.
21. Degenhardt BF, Darmani NA, Johnson JC, Towns LC, Rhodes DC,
Trinh C, et al.: Role of osteopathic manipulative treatment in
altering pain biomarkers: a pilot study.  J Am Osteopath Assoc
2007, 107:387-400.
22. Kaada B, Torsteinbo O: Increase of plasma beta-endorphins in
connective tissue massage.  Gen Pharmacol 1989, 20:487-489.
23. McPartland JM, Giuffrida A, King J, Skinner E, Scotter J, Musty RE:
Cannabimimetic effects of osteopathic manipulative treat-
ment.  J Am Osteopath Assoc 2005, 105:283-291.
24. Vernon HT, Dhami MS, Howley TP, Annett R: Spinal manipulation
and beta-endorphin: a controlled study of the effect of a spi-
nal manipulation on plasma beta-endorphin levels in normal
males.  J Manipulative Physiol Ther 1986, 9:115-123.Page 12 of 12
(page number not for citation purposes)
